News Image

Veracyte to Participate in Upcoming Investor Conferences

Provided By Business Wire

Last update: May 15, 2024

Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, today announced it will participate in the following investor conferences.

  • Leerink Partners 2024 Healthcare Crossroads Conference – Austin, TX

    Fireside Chat on May 29th at 12:20 p.m. Eastern Time
  • William Blair 44th Annual Growth Stock Conference – Chicago, IL

    Presentation on June 4th at 5:40 p.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcasts will be available following the conclusion of the live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515789405/en/

VERACYTE INC

NASDAQ:VCYT (3/7/2025, 11:38:05 AM)

32.41

-0.1 (-0.31%)



Find more stocks in the Stock Screener

VCYT Latest News and Analysis

ChartMill News Image8 days ago - ChartmillVERACYTE INC (NASDAQ:VCYT) stands out as a growth opportunity that won't break the bank.

Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.

Follow ChartMill for more